Expert Analysis and Opinion—Understanding Cardiac Amyloidosis | oneAMYLOIDOSISvoice
×
Or register here
Global Search

Trusted Resources: Education

Scientific literature and patient education texts

Back to Education / Reference Materials

Expert Analysis and Opinion—Understanding Cardiac Amyloidosis

key information

source: American College of Cardiology Foundation

year: 2021

authors: Frederick L. Ruberg, Mathew S. Maurer

summary/abstract:

Cardiac amyloidosis (CA) is a protein-folding disorder nearly exclusively caused by misfolded amyloid transthyretin (ATTR) and amyloid light chain (AL) proteins.

• Name derives from Latin “amylum” (starch like).
• Nomenclature: “A” for amyloid, followed by precursor protein abbreviation (e.g., AL = amyloid light chain amyloidosis).
• Histologic diagnosis: Aggregates of beta-sheets that stain with Congo red (green birefringence under polarized light). Congo red staining does not identify the type of amyloidosis.
• Systemic amyloidoses classified by precursor protein:
– Light chain and transthyretin (TTR) are the most common types.
– Immunoglobulin light chains are produced by the bone marrow plasma cell; circulating TTR (formerly known as “prealbumin”) is produced by the liver.
– TTR can be genetically normal (transthyretin amyloidosis wild-type [ATTRwt]) or variant (transthyretin amyloidosis variant [ATTRv] or hereditary transthyretin amyloidosis [hATTR]).
– Single-nucleotide polymorphisms in the transthyretin (TTR) gene induce TTR instability and misfolding.
 
read more

Related Content

To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences.
More information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Close

Community Key Collaborator

Support for this landing page is provided by an independent education grant from

Translation of this platform made possible through an independent education grant from

© 2024 rareLife solutions Inc.

To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences.
More information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Close